First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study Meeting Abstract
| Authors: | O'Donnell, P. H.; Balar, A. V.; Vuky, J.; Castellano, D.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Grivas, P.; Hahn, N. M.; Plimack, E. R.; Xu, J. Z.; Godwin, J. L.; Moreno, B. H.; De Wit, R. |
| Abstract Title: | First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602256 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4508 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4508 -- Source: Wos |
